(19)
(11) EP 3 338 086 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
14.08.2024 Bulletin 2024/33

(45) Mention of the grant of the patent:
03.07.2024 Bulletin 2024/27

(21) Application number: 16882553.7

(22) Date of filing: 28.12.2016
(51) International Patent Classification (IPC): 
G01N 33/48(2006.01)
G01N 33/487(2006.01)
A61P 35/00(2006.01)
A61B 8/13(2006.01)
G01N 15/14(2024.01)
G01N 33/483(2006.01)
G01N 21/64(2006.01)
A61P 35/04(2006.01)
G01N 1/40(2006.01)
G01N 33/50(2006.01)
(52) Cooperative Patent Classification (CPC):
G01N 1/40; G01N 2015/1445; G01N 33/5011; G01N 33/5026; G01N 2800/7028; A61P 35/00; A61P 35/04; G01N 15/1433; G01N 15/149
(86) International application number:
PCT/US2016/068859
(87) International publication number:
WO 2017/117210 (06.07.2017 Gazette 2017/27)

(54)

SYSTEM AND METHOD FOR AUTOMATED DETECTION AND MONITORING OF DYSPLASIA

SYSTEM UND VERFAHREN ZUR AUTOMATISIERTEN ERKENNUNG UND ÜBERWACHUNG VON DYSPLASIE

SYSTÈME ET PROCÉDÉ AUTOMATISÉ DE DÉTECTION ET DE SURVEILLANCE DE DYSPLASIE


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 30.12.2015 US 201562273127 P
26.07.2016 US 201662367000 P

(43) Date of publication of application:
27.06.2018 Bulletin 2018/26

(73) Proprietor: VisionGate, Inc.
Woodinville, WA 98072 (US)

(72) Inventors:
  • NELSON, Alan C.
    Phoenix, Arizona 85044 (US)
  • MEYER, Michael G.
    Phoenix, Arizona 85044 (US)

(74) Representative: Eisenführ Speiser 
Patentanwälte Rechtsanwälte PartGmbB Am Kaffee-Quartier 3
28217 Bremen
28217 Bremen (DE)


(56) References cited: : 
WO-A1-2005/122878
US-A1- 2003 031 352
US-A1- 2008 248 033
US-A1- 2014 139 625
WO-A2-03/025543
US-A1- 2007 054 331
US-A1- 2012 145 926
   
  • MICHAEL G. MEYER ET AL: "The Cell-CT 3-dimensional cell imaging technology platform enables the detection of lung cancer using the noninvasive LuCED sputum test : Lung Cancer Detection by LuCED", TARGET PREVALENCE INFLUENCES CYTOLOGISTS' ERROR RATES, vol. 123, no. 9, 6 July 2015 (2015-07-06), & 58TH ANNUAL SCIENTIFIC MEETING OF THE AMERICAN-SOCIETY-OF-CYTOPATHOLOGY; BOSTON, MA, USA; NOVEMBER 12 -16, 2010, pages 512 - 523, XP055512493, ISSN: 1934-662X, DOI: 10.1002/cncy.21576
  • R. L. KEITH ET AL: "Oral Iloprost Improves Endobronchial Dysplasia in Former Smokers", CANCER PREVENTION RESEARCH, vol. 4, no. 6, 30 June 2011 (2011-06-30), United States, pages 793 - 802, XP055512497, ISSN: 1940-6207, DOI: 10.1158/1940-6207.CAPR-11-0057
  • MEYER ET AL.: "The Cell -CT 3-Dimensional Cell Imaging Technology Platform Enables The Detection Of Lung Cancer Using The Noninvasive LuCED Sputum Test", CANCER CYTOPATHOLOGY, September 2015 (2015-09-01), pages 512 - 523, XP055512493, DOI: doi:10.1002/cncy.21576
  • KEITH ET AL.: "Oral Iloprost Improves Endobronchial Dysplasia In Former Smokers", CANCER PREVENTION RESEARCH,, vol. 4, no. 6, 1 June 2011 (2011-06-01) - 1 June 2012 (2012-06-01), pages 793 - 802, XP055512497, ISSN: 1940-6207, DOI: 10.1158/1940-6207.CAPR-11-0057
  • GOULD ET AL.: "Evaluation of Individuals With Pulmonary Nodules: When Is It Lung Cancer?- Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines", CHEST, vol. 143, no. 5, May 2013 (2013-05-01), pages e93s - e120s, XP055599308
  • WILBURN ET AL.: "Automated 3-Dimensional Morphologic Analysis of Sputum Specimens for Lung Cancer Detection: Performance Characteristics Support Use in Lung Cancer Screening", CANCER CYTOPATHOLOGY, September 2015 (2015-09-01), pages 548 - 556, XP055512527, DOI: doi:10.1002/cncy.21565
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).